SG11202003978UA - Molecules that bind to cd137 and psma - Google Patents
Molecules that bind to cd137 and psmaInfo
- Publication number
- SG11202003978UA SG11202003978UA SG11202003978UA SG11202003978UA SG11202003978UA SG 11202003978U A SG11202003978U A SG 11202003978UA SG 11202003978U A SG11202003978U A SG 11202003978UA SG 11202003978U A SG11202003978U A SG 11202003978UA SG 11202003978U A SG11202003978U A SG 11202003978UA
- Authority
- SG
- Singapore
- Prior art keywords
- psma
- bind
- molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1718734.5A GB201718734D0 (en) | 2017-11-13 | 2017-11-13 | Single domain antibodies that bind to CD137 |
GBGB1718735.2A GB201718735D0 (en) | 2017-11-13 | 2017-11-13 | Bispecific molecules that bind to CD137 and PSMA |
GBGB1808589.4A GB201808589D0 (en) | 2018-05-24 | 2018-05-24 | Single domain antibodies that bind CD137 |
PCT/GB2018/053280 WO2019092452A1 (en) | 2017-11-13 | 2018-11-13 | Molecules that bind to cd137 and psma |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202003978UA true SG11202003978UA (en) | 2020-05-28 |
Family
ID=64457031
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202003978UA SG11202003978UA (en) | 2017-11-13 | 2018-11-13 | Molecules that bind to cd137 and psma |
SG11202003912RA SG11202003912RA (en) | 2017-11-13 | 2018-11-13 | Single Domain Antibodies that Bind to CD137 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202003912RA SG11202003912RA (en) | 2017-11-13 | 2018-11-13 | Single Domain Antibodies that Bind to CD137 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20200362047A1 (hr) |
EP (2) | EP3710478A1 (hr) |
JP (3) | JP7312168B2 (hr) |
KR (2) | KR20200080304A (hr) |
CN (2) | CN111699197A (hr) |
AU (2) | AU2018363292A1 (hr) |
CA (2) | CA3082321A1 (hr) |
IL (2) | IL274371A (hr) |
SG (2) | SG11202003978UA (hr) |
WO (2) | WO2019092452A1 (hr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108473589B (zh) | 2016-01-12 | 2023-05-02 | 克雷森多生物制剂有限公司 | 结合前列腺特异性膜抗原(psma)的分子 |
GB201607968D0 (en) | 2016-05-06 | 2016-06-22 | Crescendo Biolog Ltd | Chimeric antigen receptor |
WO2018127710A1 (en) | 2017-01-06 | 2018-07-12 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
GB201711068D0 (en) | 2017-07-10 | 2017-08-23 | Crescendo Biologics Ltd | Therapeutic molecules binding PSMA |
WO2019092452A1 (en) * | 2017-11-13 | 2019-05-16 | Crescendo Biologics Limited | Molecules that bind to cd137 and psma |
GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
JP2020132572A (ja) * | 2019-02-20 | 2020-08-31 | 旭化成株式会社 | シラノール組成物、硬化物及び製造方法 |
US20220220215A1 (en) * | 2019-05-15 | 2022-07-14 | Crescendo Biologics Limited | Binding molecules |
WO2021027850A1 (en) * | 2019-08-12 | 2021-02-18 | I-Mab Biopharma Co., Ltd. | Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof |
AU2020381735A1 (en) * | 2019-11-13 | 2022-05-26 | Hefei Hankemab Biotechnology Co., Ltd | Molecule capable of binding to human 4-1BB, and application of molecule |
IL293046A (en) * | 2019-11-18 | 2022-07-01 | Janssen Biotech Inc | Anti-cd79 chimeric antigen receptors, car-t cells and uses thereof |
US20230242658A1 (en) * | 2020-06-30 | 2023-08-03 | Nona Biosciences (Suzhou) Co., Ltd. | 4-1bb-binding protein and use thereof |
MX2023003041A (es) | 2020-09-16 | 2023-05-09 | Amgen Inc | Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer. |
CN117460745A (zh) * | 2021-05-21 | 2024-01-26 | 百济神州有限公司 | 抗gpc3和抗cd137多特异性抗体及使用方法 |
CN117355540A (zh) * | 2021-05-21 | 2024-01-05 | 百济神州有限公司 | 抗cd137抗体和使用方法 |
CN113621065B (zh) * | 2021-08-30 | 2023-08-01 | 武汉海沙百得生物技术有限公司 | 靶向4-1bb的全人源抗体及其制备方法和应用 |
IL311144A (en) * | 2021-08-31 | 2024-04-01 | Lanova Medicines Ltd | Anti-1-4BB Nanobodies |
WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
WO2024061364A1 (zh) * | 2022-09-22 | 2024-03-28 | 成都盛世君联生物技术有限公司 | 一种抗4-1bb纳米抗体及其制备和应用 |
WO2024109678A1 (en) * | 2022-11-21 | 2024-05-30 | Beigene, Ltd. | Anti-cd137 antibodies and methods of use |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
GB2398784B (en) | 2003-02-26 | 2005-07-27 | Babraham Inst | Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal |
SG10201606980VA (en) * | 2004-06-03 | 2016-10-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
GB0521621D0 (en) * | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
EP2310526A4 (en) * | 2008-07-18 | 2011-11-02 | Oragenics Inc | COMPOSITIONS FOR THE DETECTION AND TREATMENT OF COLORECTAL CANCER |
US9120855B2 (en) * | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
ES2715279T3 (es) * | 2012-05-24 | 2019-06-03 | Vib Vzw | Dominios variables individuales inmunoglobulínicos anti-receptor de manosa de macrófagos para elegir como diana y obtener imágenes in vivo de macrófagos asociados a tumores |
WO2014141192A1 (en) | 2013-03-15 | 2014-09-18 | Erasmus University Medical Center | Generation of heavy chain-only antibodies |
EP3130606B1 (en) * | 2014-04-07 | 2021-10-13 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating bispecific antibodies |
US10092645B2 (en) * | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
AU2014409276A1 (en) * | 2014-10-22 | 2017-04-06 | Crescendo Biologics Limited | Transgenic mice |
US10865250B2 (en) | 2015-05-04 | 2020-12-15 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
ES2938525T3 (es) * | 2015-05-18 | 2023-04-12 | Pieris Pharmaceuticals Gmbh | Polipéptido de fusión anticanceroso |
PE20181349A1 (es) * | 2015-10-07 | 2018-08-22 | Hoffmann La Roche | Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador |
IL260530B2 (en) * | 2016-01-11 | 2024-01-01 | Inhibrx Inc | Multispecific and multivalent 41BB-binding fusion proteins, preparations containing them and their uses |
CN108473589B (zh) * | 2016-01-12 | 2023-05-02 | 克雷森多生物制剂有限公司 | 结合前列腺特异性膜抗原(psma)的分子 |
WO2017182672A1 (en) * | 2016-04-22 | 2017-10-26 | Alligator Bioscience Ab | Novel bispecific polypeptides against cd137 |
EP3464367B1 (en) * | 2016-05-27 | 2020-09-09 | AbbVie Biotherapeutics Inc. | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen |
SG11202002982YA (en) * | 2017-10-10 | 2020-04-29 | Numab Therapeutics AG | Multispecific antibody |
WO2019092452A1 (en) * | 2017-11-13 | 2019-05-16 | Crescendo Biologics Limited | Molecules that bind to cd137 and psma |
-
2018
- 2018-11-13 WO PCT/GB2018/053280 patent/WO2019092452A1/en active Application Filing
- 2018-11-13 JP JP2020526175A patent/JP7312168B2/ja active Active
- 2018-11-13 KR KR1020207016093A patent/KR20200080304A/ko not_active Application Discontinuation
- 2018-11-13 AU AU2018363292A patent/AU2018363292A1/en active Pending
- 2018-11-13 JP JP2020526245A patent/JP2021502810A/ja active Pending
- 2018-11-13 SG SG11202003978UA patent/SG11202003978UA/en unknown
- 2018-11-13 EP EP18808058.4A patent/EP3710478A1/en active Pending
- 2018-11-13 KR KR1020207016092A patent/KR20200083574A/ko not_active Application Discontinuation
- 2018-11-13 CN CN201880085847.0A patent/CN111699197A/zh active Pending
- 2018-11-13 CA CA3082321A patent/CA3082321A1/en active Pending
- 2018-11-13 WO PCT/GB2018/053279 patent/WO2019092451A1/en active Application Filing
- 2018-11-13 US US16/763,059 patent/US20200362047A1/en active Pending
- 2018-11-13 SG SG11202003912RA patent/SG11202003912RA/en unknown
- 2018-11-13 CA CA3082297A patent/CA3082297A1/en active Pending
- 2018-11-13 EP EP18808057.6A patent/EP3710477A1/en active Pending
- 2018-11-13 AU AU2018363291A patent/AU2018363291A1/en active Pending
- 2018-11-13 US US16/763,063 patent/US20200362051A1/en active Pending
- 2018-11-13 CN CN201880086045.1A patent/CN111683968A/zh active Pending
-
2020
- 2020-04-30 IL IL274371A patent/IL274371A/en unknown
- 2020-04-30 IL IL274370A patent/IL274370A/en unknown
-
2023
- 2023-07-06 JP JP2023111710A patent/JP2023126951A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200362047A1 (en) | 2020-11-19 |
WO2019092452A1 (en) | 2019-05-16 |
KR20200080304A (ko) | 2020-07-06 |
JP7312168B2 (ja) | 2023-07-20 |
IL274371A (en) | 2020-06-30 |
CN111699197A (zh) | 2020-09-22 |
JP2021502810A (ja) | 2021-02-04 |
CN111683968A (zh) | 2020-09-18 |
JP2021502104A (ja) | 2021-01-28 |
JP2023126951A (ja) | 2023-09-12 |
SG11202003912RA (en) | 2020-05-28 |
EP3710477A1 (en) | 2020-09-23 |
AU2018363291A1 (en) | 2020-05-21 |
WO2019092451A1 (en) | 2019-05-16 |
CA3082297A1 (en) | 2019-05-16 |
IL274370A (en) | 2020-06-30 |
US20200362051A1 (en) | 2020-11-19 |
CA3082321A1 (en) | 2019-05-16 |
EP3710478A1 (en) | 2020-09-23 |
AU2018363292A1 (en) | 2020-05-21 |
KR20200083574A (ko) | 2020-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL274371A (en) | Compounds that bind CD137 and PSMA | |
IL273631A (en) | Special hpv molecules bind | |
IL266100B (en) | Multimeric il-15 based molecules | |
HK1252863A1 (zh) | 結合cd22的抗體分子 | |
HK1254337A1 (zh) | April的抗體分子及其用途 | |
IL254223A (en) | CD20 binding compounds and their uses | |
GB201612520D0 (en) | Binding molecules | |
SG11201705583XA (en) | Cxcr4 binding molecules | |
GB201702091D0 (en) | Specific binding molecules | |
SG11202004904XA (en) | Binding molecules that specifically bind to tau | |
HK1258317A1 (zh) | 對asct2具有特異性的結合分子及其用途 | |
IL269752B (en) | fgfr3 binding molecules | |
IL259883A (en) | Antibody molecules that bind tnf alpha | |
GB201718735D0 (en) | Bispecific molecules that bind to CD137 and PSMA | |
GB201718734D0 (en) | Single domain antibodies that bind to CD137 | |
GB201508729D0 (en) | Binding molecules |